المستخلص: |
Sickle cell anemia results from the replacement of the amino acid “glutamic” by “valine” on the 6 position on the Beta chain. This results in the crystallization of haemoglobin, rigidity of the cell and development of haemolytic anaemia and impairment in the function of some organs. Aim: To high light the benefit of the administration of Hydorxyurea as a first choice in the management of sickle cell anaemia usually in the severe cases. Materials and methods: Anticoagulated specimens were collected. Screen test and solubility test were carried out. On positive results Hb – electrophoresis was applied to differentiate between sickle cell trait (A/S) and sickle cell disease (S/S). In patient with severe sickle cell anaemia Hydroxyurea was administrated. Hb – F level was done pre and post treatment to evaluate the response of the drug. The results showed that Hb – F level was significantly elevated (P ≤ 0.001) after treatment with Hydroxyuea and will give protection to red cells containing Hb – S. This study concluded that, Hydroxyurea increases markedly the level of Hb – F consequently protect the red cell against sickling phenomenon, thus increases life span of red cells.
|